Literature DB >> 19135771

Expression of P190 and P210 BCR/ABL1 in normal human CD34(+) cells induces similar gene expression profiles and results in a STAT5-dependent expansion of the erythroid lineage.

Marcus Järås1, Petra Johnels, Helena Agerstam, Carin Lassen, Marianne Rissler, Patrik Edén, Jörg Cammenga, Tor Olofsson, Ole Weis Bjerrum, Johan Richter, Xiaolong Fan, Thoas Fioretos.   

Abstract

OBJECTIVE: The P190 and P210 BCR/ABL1 fusion genes are mainly associated with different types of hematologic malignancies, but it is presently unclear whether they are functionally different following expression in primitive human hematopoietic cells.
MATERIALS AND METHODS: We investigated and systematically compared the effects of retroviral P190 BCR/ABL1 and P210 BCR/ABL1 expression on cell proliferation, differentiation, and global gene expression in human CD34(+) cells from cord blood.
RESULTS: Expression of either P190 BCR/ABL1 or P210 BCR/ABL1 resulted in expansion of erythroid cells and stimulated erythropoietin-independent burst-forming unit-erythroid colony formation. By using a lentiviral anti-signal transducer and activator of transcription 5 (STAT5) short-hairpin RNA, we found that both P190 BCR/ABL1- and P210 BCR/ABL1-induced erythroid cell expansion were STAT5-dependent. Under in vitro conditions favoring B-cell differentiation, neither P190 nor P210 BCR/ABL1-expressing cells formed detectable levels of CD19-positive cells. Gene expression profiling revealed that P190 BCR/ABL1 and P210 BCR/ABL1 induced almost identical gene expression profiles.
CONCLUSIONS: Our data suggest that the early cellular and transcriptional effects of P190 BCR/ABL1 and P210 BCR/ABL1 expression are very similar when they are expressed in the same human progenitor cell population, and that STAT5 is an important regulator of BCR/ABL1-induced erythroid cell expansion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19135771     DOI: 10.1016/j.exphem.2008.11.003

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  4 in total

1.  Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.

Authors:  Marcus Järås; Petra Johnels; Nils Hansen; Helena Agerstam; Panagiotis Tsapogas; Marianne Rissler; Carin Lassen; Tor Olofsson; Ole Weis Bjerrum; Johan Richter; Thoas Fioretos
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-30       Impact factor: 11.205

2.  Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression.

Authors:  Philip A Beer; David J H F Knapp; Paul H Miller; Nagarajan Kannan; Ivan Sloma; Kathy Heel; Sonja Babovic; Elizabeth Bulaeva; Gabrielle Rabu; Jefferson Terry; Brian J Druker; Marc M Loriaux; Keith R Loeb; Jerald P Radich; Wendy N Erber; Connie J Eaves
Journal:  Blood       Date:  2014-11-04       Impact factor: 22.113

3.  Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets.

Authors:  Shady Adnan-Awad; Daehong Kim; Helena Hohtari; Komal Kumar Javarappa; Tania Brandstoetter; Isabella Mayer; Swapnil Potdar; Caroline A Heckman; Soili Kytölä; Kimmo Porkka; Eszter Doma; Veronika Sexl; Matti Kankainen; Satu Mustjoki
Journal:  Leukemia       Date:  2020-11-09       Impact factor: 11.528

4.  SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function.

Authors:  N Hansen; H Ågerstam; M Wahlestedt; N Landberg; M Askmyr; M Ehinger; M Rissler; H Lilljebjörn; P Johnels; J Ishiko; J V Melo; W S Alexander; D Bryder; M Järås; T Fioretos
Journal:  Leukemia       Date:  2012-06-22       Impact factor: 11.528

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.